Holen Sie sich die Stockscreener-App
5.1881
3.55%
0.1781
Schlusskurs vom Vortag:
$5.01
Offen:
$5.01
24-Stunden-Volumen:
22,311
Relative Volume:
1.21
Marktkapitalisierung:
$55.47M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-33.82M
KGV:
-0.1956
EPS:
-26.5174
Netto-Cashflow:
$-66.04M
1W Leistung:
-4.81%
1M Leistung:
+5.02%
6M Leistung:
-41.44%
1J Leistung:
-0.04%
1-Tages-Spanne:
$5.01
$5.4781
1-Wochen-Bereich:
$4.90
$5.54
52-Wochen-Spanne:
$2.96
$11.45
Elicio Therapeutics Inc Stock (ELTX) Company Profile
Firmenname
Elicio Therapeutics Inc
Sektor
Branche
Telefon
(857) 209-0050
Adresse
451 D STREET, 5TH FLOOR, BOSTON
Vergleichen Sie ELTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| ELTX | 5.19 | 55.47M | 0 | -33.82M | -66.04M | -26.52 |
| VRTX | 450.39 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 749.43 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.59 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.94 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 106.90 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Elicio Therapeutics Inc Aktie (ELTX) Neueste Nachrichten
Elicio Therapeutics: Q3 Earnings Snapshot - mySA
Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewswire
Elicio Therapeutics adjourns annual meeting due to lack of quorum - Investing.com
Elicio reports promising Phase 1 cancer vaccine trial results - Investing.com India
Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual Meeting - GlobeNewswire
Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study - The Bakersfield Californian
Elicio Therapeutics adjourns annual meeting due to lack of quorum By Investing.com - Investing.com UK
Jones Trading Initiates Coverage of Elicio Therapeutics (ELTX) with Buy Recommendation - MSN
Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit - The Manila Times
Elicio Therapeutics to Present Clinical Data at the Society - GlobeNewswire
All You Need to Know About Elicio Therapeutics (ELTX) Rating Upgrade to Strong Buy - Yahoo Finance
Elicio Therapeutics announces new CFO and accounting officer By Investing.com - Investing.com Australia
Elicio Therapeutics announces new CFO and accounting officer - Investing.com
Elicio Therapeutics reports inducement grants - TipRanks
Elicio Therapeutics Reports Inducement Grants - GlobeNewswire
Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted - The Bakersfield Californian
Elicio Therapeutics Announces Three Upcoming Presentations - GlobeNewswire
Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines - StockTitan
KalVista Appoints Brian Piekos as Chief Financial Officer - Business Wire
Elicio Therapeutics CFO resigns to pursue new opportunity By Investing.com - Investing.com Australia
Elicio Therapeutics CFO resigns to pursue new opportunity - Investing.com
Elicio Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewswire
ELTX Stock Earnings: Elicio Therapeutics Beats EPS for Q2 2024 - InvestorPlace
Elicio Therapeutics Announces Closing of Private Placement of $20.0 Million Convertible Note - GlobeNewswire
Elicio Therapeutics’ US$40 Million ATM and US$11.5 Million Public Offering - Global Legal Chronicle
Therapeutic Vaccine Industry to Witness Massive Growth - openPR
ASCO 2024Chris Haqq - pharmaphorum
Ratios in Focus: Analyzing Elicio Therapeutics Inc. (ELTX)'s Price-to-Cash and Price-to-Free Cash Flow – DWinneX - The Dwinnex
Why Is Cancer Vaccine Developer Elicio Therapeutics Stock Trading Lower On Friday? - MSN
Elicio Therapeutics sets $11.5 million stock offering By Investing.com - Investing.com Australia
Orion Group Holdings inks $30.5M land sale deal By Investing.com - Investing.com
Apple shares target raised, reiterates Outperform on AI potential By Investing.com - Investing.com
Elicio Therapeutics Shares Drop 35% After Public Offering Prices - MarketWatch
Elicio Therapeutics Prices of $11.5 Million Underwritten Public Offering - citybiz
Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering - GlobeNewswire
Why Is Elicio Therapeutics (ELTX) Stock Down 36% Today? - InvestorPlace
Elicio Therapeutics launches public offering of stock and warrants By Investing.com - Investing.com Australia
Elicio reports promising early results in cancer vaccine trial By Investing.com - Investing.com Australia
Finanzdaten der Elicio Therapeutics Inc-Aktie (ELTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):